Induction of apoptosis in nasal polyp-derived fibroblasts by bleomycin A5 in vitro

Cromolyn sodium and masitinib combination inhibits fibroblast-myofibroblast transition and exerts additive cell-protective and antioxidant effects on a bleomycin-induced in vitro fibrosis model

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrotic lung disease. While recent studies have suggested the potential efficacy of tyrosine kinase inhibitors in managing IPF, masitinib, a clinically used tyrosine kinase inhibitor, has not yet been investigated for its efficacy in fibrotic lung diseases. In a previous study on an in vitro neurodegenerative model, we demonstrated the synergistic antitoxic and antioxidant effects of masitinib combined with cromolyn sodium, an FDA-approved mast cell stabilizer. This study aims to investigate the anti-fibrotic and antioxidant effects of the masitinib-cromolyn sodium combination in an in vitro model of pulmonary fibrosis. Fibroblast cell cultures treated with bleomycin and/or hydrogen peroxide (H2O2) were subjected to masitinib and/or cromolyn sodium, followed by assessments of cell viability, morphological and apoptotic nuclear changes, triple-immunofluorescence labeling, and total oxidant/antioxidant capacities, besides ratio of Bax and Bcl-2 mRNA expressions as an indication of apoptosis. The combined treatment of masitinib and cromolyn sodium effectively prevented the fibroblast myofibroblast transition, a hallmark of fibrosis, and significantly reduced bleomycin / H2O2-induced apoptosis and oxidative stress. This study is the first to demonstrate the additive anti-fibrotic, cell-protective, and antioxidant effects of the masitinib-cromolyn sodium combination in an in vitro fibrosis model, suggesting its potential as an innovative therapeutic approach for pulmonary fibrosis. Combination therapy may be more advantageous in that both drugs could be administered in lower doses, exerting less side effects, and at the same time providing diverse mechanisms of action simultaneously.

Effect of Thymoquinone and Transforming Growth Factor-β1 on the Cell Viability of Nasal Polyp-Derived Fibroblast

BACKGROUND: Nasal polyps are benign masses in the nasal cavity and the abnormal growth of sinonasal tissue due to a chronic inflammatory process. Many fibroblasts populate the nasal polyp stroma release cytokines such as Transforming Growth Factor (TGF) and producing a variety of cytokines resulting in inflammatory cell infiltration. Thymoquinone (TQ) is the main active component in Nigella sativa oil and has the ability to reduces cell viability in many cancer cell line. AIM: The purpose of this study was to determine the effect of TQ and TGF-β1 on cell viability of Nasal Polyp-Derived Fibroblast. MATERIALS AND METHODS: Nasal polyp-derived fibroblasts were isolated from nasal polyp specimen and treated with various concentrations of TQ at 1–1000 μM and TGF-β1 at 5 ng/ml to determine the cell viability using the Cell Counting Kit-8 assay after 48 h incubation. RESULTS: TQ significantly reduced the viability of nasal polyp fibroblast cells to 72.49% at 20 μM and reduced to 5% at 50 μM until 1000 μM with IC50 at 21.93 μM. TGF-β1 at 5 ng/ml significantly reduced the viability of nasal polyp fibroblast cells to 81.96% and TGF-β1 appears to have a dual effect that depends on the concentration of TQ. CONCLUSION: This study proved that TQ and TGF-β1 were able to reduce the viability of nasal polyp fibroblast cells.